AstraZeneca

3 standout digital innovations in pharma this year
3 standout digital innovations in pharma this year
Pharma Voice
IDEA Pharma
innovation
digital pharma
AstraZeneca
Roche
Boehringer Ingelheim
Flag link:
AstraZeneca, AI biologics firm Absci tie up on cancer drug
AstraZeneca, AI biologics firm Absci tie up on cancer drug
Reuters
AstraZeneca
Absci
artificial intelligence
cancer
Flag link:
AstraZeneca calls off two late-stage potassium drug trials
AstraZeneca calls off two late-stage potassium drug trials
Reuters
AstraZeneca
clinical trials
Lokelma
hyperkalemia
Flag link:
J&J Seeks Expanded Use of Lung Cancer Drug Rybrevant
J&J Seeks Expanded Use of Lung Cancer Drug Rybrevant
Yahoo/Zacks.com
JNJ
Rybevant
non-small cell lung cancer
AstraZeneca
Tagrisso
Flag link:
AstraZeneca’s Imfinzi Phase III trial raises trial design questions
AstraZeneca’s Imfinzi Phase III trial raises trial design questions
Clinical Trials Arena
AstraZeneca
Imfinzi
clinical trials
Flag link:
Senate Democrats press Sanofi and AZ for answers as 'unprecedented' demand spurs shortage of RSV antibody Beyfortus
Senate Democrats press Sanofi and AZ for answers as 'unprecedented' demand spurs shortage of RSV antibody Beyfortus
Fierce Pharma
Sanofi
AstraZeneca
Senate
CDC
RSV
Beyfortus
drug shortages
Flag link:
The Next Generation of Weight Loss Drugs is Rapidly Approaching
The Next Generation of Weight Loss Drugs is Rapidly Approaching
BioSpace
weightloss
Novo Nordisk
Eli Lilly
Pfizer
AstraZeneca
Wegovy
Zepbound
Flag link:
AZ launches digital clinical trials business
AZ launches digital clinical trials business
Pharmaphorum
AstraZeneca
clinical trials
Evinova
Flag link:
AstraZeneca’s AKT Inhibitor Wins FDA Approval for Combo Breast Cancer Treatment
AstraZeneca’s AKT Inhibitor Wins FDA Approval for Combo Breast Cancer Treatment
BioSpace
AstraZeneca
Truqap
breast cancer
Flag link:
FDA Approves Truqap Plus Faslodex for Advanced HR-Positive Breast Cancer
FDA Approves Truqap Plus Faslodex for Advanced HR-Positive Breast Cancer
Pharm Exec
AstraZeneca
Truqap
breast cancer
HR-positive
Flag link:
AstraZeneca Bid to Expand Imfinzi’s NSCLC Label Hit with Phase III Flop
AstraZeneca Bid to Expand Imfinzi’s NSCLC Label Hit with Phase III Flop
BioSpace
AstraZeneca
Imfinzi
clinical trials
non-small cell lung cancer
Flag link:
AstraZeneca’s Imfinzi meets PFS primary endpoint in Phase III HCC trial
AstraZeneca’s Imfinzi meets PFS primary endpoint in Phase III HCC trial
Clinical Trials Arena
AstraZeneca
clinical trials
Imfinzi
hepatocellular carcinoma
Flag link:
AstraZeneca pays $185M upfront to reenter oral obesity gold rush, drops phase 2 sickle cell drug
AstraZeneca pays $185M upfront to reenter oral obesity gold rush, drops phase 2 sickle cell drug
Fierce Biotech
AstraZeneca
obesity
sickle cell disease
Eccogene
earnings
Flag link:
AbbVie, AstraZeneca, Boehringer and more face FTC's ire for 'improper' patent listings
AbbVie, AstraZeneca, Boehringer and more face FTC's ire for 'improper' patent listings
Fierce Pharma
FTC
Orange Book
patents
AbbVie
AstraZeneca
Boehringer Ingelheim
Flag link:
RSV is on the rise but preventative drugs are in short supply
RSV is on the rise but preventative drugs are in short supply
MIT Technology Review
RSV
CDC
vaccines
nirsevimab
drug shortages
AstraZeneca
Flag link:
AstraZeneca's failed cancer drug gets new lease on life thanks to positive kidney disease data
AstraZeneca's failed cancer drug gets new lease on life thanks to positive kidney disease data
Fierce Biotech
AstraZeneca
zibotentan
chronic kidney disease
Flag link:
HHS Challenges AstraZeneca’s Motion for Summary Judgement in IRA Lawsuit
HHS Challenges AstraZeneca’s Motion for Summary Judgement in IRA Lawsuit
BioSpace
AstraZeneca
legal
HHS
Inflation Reduction Act
Flag link:
Merck's Keytruda nabs FDA nod in biliary tract cancer, catching up with AstraZeneca's Imfinzi
Merck's Keytruda nabs FDA nod in biliary tract cancer, catching up with AstraZeneca's Imfinzi
Fierce Pharma
Merck
AstraZeneca
biliary tract cancer
Keytruda
Imfinzi
Flag link:
AstraZeneca Drops $245M on Cell and Gene Therapies in Deal with Cellectis
AstraZeneca Drops $245M on Cell and Gene Therapies in Deal with Cellectis
BioSpace
AstraZeneca
Cellectis
cell therapy
gene therapy
Flag link:
Merck KGaA pays $169M for selective PARP1 drug, stepping up challenge to AstraZeneca and Gilead
Merck KGaA pays $169M for selective PARP1 drug, stepping up challenge to AstraZeneca and Gilead
Fierce Biotech
Merck KGaA
PARP inhibitors
Lynparza
Zejula
AstraZeneca
Gilead Sciences
solid tumors
Flag link:

Pages